ERBB2 and cancer: PREDIX HER2 trial demonstrated similar efficacy and less toxicity favouring neoadjuvant TDM-1 monotherapy when compared to pertuzumab, trastuzumab, and docetaxel, particularly in patients with HER2+/HR+ cancers [48].